Directors

The Board of Malin Corporation plc is comprised of 8 Directors, of whom 3 have executive functions.

  • Chairman Kyran McLaughlin
  • Chief Executive Officer Kelly Martin
  • Chief Investment Officer Adrian Howd, Ph.D
  • Chief Financial Officer Darragh Lyons
  • Lead Independent Non-Executive Director Liam Daniel
  • Independent Non-Executive Director Owen Hughes
  • Independent Non-Executive Director Robert A. Ingram
  • Independent Non-Executive Director Kieran McGowan

Profiles of the individual Directors are set out below:

Kyran McLaughlin — Chairman

Mr. McLaughlin is currently Deputy Chairman and Head of Capital Markets at Davy and holds a number of public and private company directorships, including Ryanair plc. Mr. McLaughlin is also a past director of Elan from December 1998 to its sale to Perrigo Company in December 2013 and was Chairman of Elan from January 2005 to January 2011.

Kelly Martin — Chief Executive Officer

Kelly Martin served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards. Mr. Martin is a co-founder and non-executive director of BPI.

Adrian Howd, Ph.D — Chief Investment Officer

Dr. Adrian Howd has held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a Ph.D in molecular neuroscience from the University of London. Dr. Howd is a non-executive director of BPI.

Darragh Lyons — Chief Financial Officer

Darragh Lyons is a chartered accountant and worked in a number of senior finance positions in Elan, most recently serving as the Head of Group Finance (prior to the sale of Elan to Perrigo) where he was responsible for all aspects of internal and external reporting as well as overseeing the transactional and financing activities of the company. Prior to joining Elan, Mr. Lyons worked with PricewaterhouseCoopers in Dublin, the United States and Canada, and also served in the firm’s Global Technical Accounting Group.

Liam Daniel — Lead Independent Non-Executive Director

Liam Daniel is a non-executive director of Horizon Pharma plc since September 2014 and was President of the Institute of Directors in Ireland from 2013 to 2015 having been elected to the Board of that Institute in June 2010. He served with Elan from 1993 until 2014 in various roles including Controller, Company Secretary, Executive Vice President and as an Executive Director. Following Elan’s acquisition by Perrigo Company in December 2013, Mr. Daniel retired from Elan in March 2014. He is a graduate of University College Dublin, a Fellow of Chartered Accountants Ireland and a Chartered Director.

Owen Hughes — Independent Non-Executive Director

Owen Hughes currently serves as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, a late stage diabetes company and as a Director of Radius Health, a Phase 3 osteoporosis company. Prior to Intarcia, Mr. Hughes served as a Director at Brookside Capital, a multi-billion dollar hedge fund that falls under the Bain Capital umbrella. There, he co-managed public and private healthcare investments including those in the biotechnology, med-tech, and services segments. Mr. Hughes has over 16 years of Wall Street experience on both the buy and sell-side.

Robert A. Ingram — Independent Non-Executive Director

Robert Ingram is the former CEO/chairman of GlaxoWellcome where he co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. He currently serves as a general partner of Hatteras Venture Partners. He previously served as chairman of Elan from 2010 until its sale to Perrigo Company in December 2013. Mr. Ingram was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on cancer, and he was awarded the Martin Luther King, Jr. Legacy Award for International Service in January 2004.

Kieran McGowan — Independent Non-Executive Director

Kieran McGowan is currently Chairman of Appian Asset Management. From 1990 until his retirement in December 1998, Mr. McGowan was chief executive of the Industrial Development Authority of Ireland. Up until May 2012, he was chairman of CRH plc, and has sat on the board of a number of private companies. He is a director of Charles Schwab Worldwide Funds plc. Mr. McGowan is also a past director of Elan Corporation plc from December 1998 to its sale to Perrigo Company in December 2013. He has served as president of the Irish Management Institute and has chaired the Governing Authority at University College Dublin. Mr. McGowan is also a member of the panel of scientific and corporate advisory partners of BPI.